70
Participants
Start Date
April 20, 2018
Primary Completion Date
July 18, 2019
Study Completion Date
July 18, 2019
Ranibizumab 0.5mg
3 intravitreal injections of ranibizumab 0.5mg, approximately 1 month apart
THR-317 8mg
3 intravitreal injections of THR-317 8mg, approximately 1 month apart
Sham injection
3 sham injections, approximately 1 month apart. No actual injections. No medication is used.
RétinElysée, Lausanne
CHU Brugmann, Brussels
UZ Leuven, Leuven
Charite Universitaetsmedizin Berlin, Berlin
Hôpital Saint-Joseph, Marseille
CHU Dijon, Dijon
Vissum Madrid, Madrid
Centre Rétine Gallien, Bordeaux
Philipps-Universität Marburg, Marburg
Hospital General Universitario de Valencia, Valencia
Oftalvist IMED Valencia, Valencia
Hospital Universitario Miguel Servet, Zaragoza
Hôpital Privé La Louvière, Lille
Universitaetsklinikum Frankfurt, Frankfurt am Main
Centre Ophtalmologique Maison Rouge, Strasbourg
Klinikum der Stadt Ludwigshafen am Rhein, Ludwigshafen am Rhein
Hôpital de la Croix Rousse, Lyon
Centre Ophtalmologique de l'Odéon, Paris
Hôpital Lariboisière, Paris
Centre Hospitalier Intercommunal de Créteil, Créteil
Centre Hospitalier Universitaire de Nice, Hôpital Pasteur, Nice
Universitaetsklinikum Dresden, Dresden
Universitaetsklinikum Leipzig, Leipzig
Univerzitná nemocnica Bratislava, Nemocnica Ružinov, Bratislava
Univerzitná nemocnica Bratislava, Nemocnica Sv. Cyrila a Metoda, Bratislava
Nemocnica Poprad, a.s., Poprad
Fakultná nemocnica Trenčín, Trenčín
Fakultná nemocnica s polikliniku Žilina, Žilina
Centro Médico Téknon, Barcelona
Hospital Clinic de Barcelona, Barcelona
Hospital general de Cataluña, Barcelona
Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat
Royal Surrey County Hospital NHS Foundation Trust, Guildford
Leeds Teaching Hospitals NHS Trust, Leeds
Moorfields Eye Hospital NHS Foundation Trust, London
Kings College Hospital NHS Foundation Trust, London
City Hospitals Sunderland NHS Foundation Trust, Sunderland
Lead Sponsor
Oxurion
INDUSTRY